Linagliptin (Tradjenta)

Linagliptin is a recent addition to the dipeptidyl peptidase IV (DPP-IV) inhibitor family. Approved by the FDA in 2011, linagliptin is used to treat type 2 diabetes by stimulating the pancreas to produce insulin.

Linagliptin overview

Brand names: Linagliptin is marketed as Tradjenta.

Drug class: Tradjenta belongs to a class of drugs known as dipeptidyl peptidase IV (DPP-IV) inhibitors. DPP-IV inhibitors are designed to break down incretin hormones (GLP-1 and GIP), which signals the pancreas to increase the production of insulin.

Dosage: Tradjenta comes in an oral tablet and is typically taken once daily, with or without food. The recommended dosage for adults is 5 mg. Individuals with type 1 diabetes should not take Tradjenta.

Side effects: The most common side effects of linagliptin are runny or stuffy nose, headache and joint pain.

Sign up for our newsletter

Thank You for Subscribing

You will receive your first newsletter soon.

Get diabetes suppliesdelivered to your door.

Find companies that offer freedelivery of the brands you want.

required field
Diabetes supplies
CPAP mask and tubing

Do you or someone you care for currently use a CPAP or BiPap sleep mask?